多利培南：一种新型碳青霉烯类抗生素——比较抗菌和杀菌活性的综述。
Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities.
机构信息
Department of Clinical Microbiology, Trinity College Dublin Dublin, Ireland.
出版信息
Ther Clin Risk Manag. 2007 Oct;3(5):789-94.
Abstract
Doripenem is a new parental 1-beta-methyl carbapenem which, unlike imipenem, does not require the addition of cilastatin on administration because of the protection afforded to doripenem by the 1-beta-methyl component. It combines the in vitro activities of imipenem and ertapenem against gram-positive bacteria with the in vitro activity of meropenem against gram-negative bacteria. It has excellent bactericidal activity against Streptococcus neumoniae. Carbapenem resistant mutants were selected with less frequency and lower minimum inhibitory concentrations (MICs) after exposure to doripenem than to imipenem or meropenem. High concentration levels of doripenem may be achieved in plasma. The half life of doripenem is higher than imipenem or meropenem. This new antibiotic has excellent in vitro activity and pharmacological properties. but how it may best be utilized still needs to be determined.
摘要
多利培南是一种新型的母体 1-β-甲基碳青霉烯类抗生素，与亚胺培南不同，由于 1-β-甲基成分的保护，多利培南不需要在给药时添加西司他丁。它结合了亚胺培南和厄他培南对革兰氏阳性菌的体外活性，以及美罗培南对革兰氏阴性菌的体外活性。它对肺炎链球菌具有极好的杀菌活性。与亚胺培南或美罗培南相比，多利培南暴露后选择碳青霉烯耐药突变体的频率较低，最低抑菌浓度（MIC）也较低。多利培南在血浆中的浓度可能很高。多利培南的半衰期高于亚胺培南或美罗培南。这种新型抗生素具有极好的体外活性和药理学特性。但如何最好地利用它仍有待确定。
相似文献
1
Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities.多利培南：一种新型碳青霉烯类抗生素——比较抗菌和杀菌活性的综述。
Ther Clin Risk Manag. 2007 Oct;3(5):789-94.
2
Comparative review of the carbapenems.碳青霉烯类药物的比较性综述。
Drugs. 2007;67(7):1027-52. doi: 10.2165/00003495-200767070-00006.
3
Doripenem versus bacteria: an emerging battleground.多利培南与细菌：一个新的战场。
J Chemother. 2009 Nov;21(5):482-92. doi: 10.1179/joc.2009.21.5.482.
4
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.多利培南（一种用于治疗由革兰氏阴性菌引起的难治性感染的碳青霉烯类药物）对来自美国的近期临床分离株的体外活性。
Antimicrob Agents Chemother. 2008 Dec;52(12):4388-99. doi: 10.1128/AAC.00381-08. Epub 2008 Sep 8.
5
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.多利培南（S-4661），一种新型碳青霉烯类抗生素：对当代病原体的比较活性，包括杀菌作用和初步体外方法评估。
J Antimicrob Chemother. 2004 Jul;54(1):144-54. doi: 10.1093/jac/dkh298. Epub 2004 Jun 9.
6
7
Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.2009 年台湾地区监控多重抗药性细菌计划（SMART）研究：从台湾加护病房分离之临床重要革兰氏阴性杆菌对于不同碳青霉烯类药品之感受性与不感受性之符合情形。
Int J Antimicrob Agents. 2013 May;41(5):457-62. doi: 10.1016/j.ijantimicag.2013.02.001. Epub 2013 Mar 16.
8
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
9
Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.评估静脉用抗生素对哥伦比亚流行的革兰氏阴性菌的药效学特征。
Braz J Infect Dis. 2011 Sep-Oct;15(5):413-9. doi: 10.1016/s1413-8670(11)70221-5.
10
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.多利培南与其他三种碳青霉烯类药物针对具有不同β-内酰胺酶耐药机制的革兰氏阴性杆菌的比较活性。
Diagn Microbiol Infect Dis. 2005 May;52(1):71-4. doi: 10.1016/j.diagmicrobio.2004.12.008.
引用本文的文献
1
Co-existence of antibiotic resistance and virulence factors in carbapenem resistant Klebsiella pneumoniae clinical isolates from Alexandria, Egypt.埃及亚历山大的耐碳青霉烯类肺炎克雷伯菌临床分离株中抗生素耐药性和毒力因子的共存。
BMC Microbiol. 2024 Nov 11;24(1):466. doi: 10.1186/s12866-024-03600-1.
2
and efficacy study of cefepime, doripenem, tigecycline, and tetracycline against extended-spectrum beta-lactamases in chickens.头孢吡肟、多利培南、替加环素和四环素对鸡体内超广谱β-内酰胺酶的疗效研究
Vet World. 2020 Mar;13(3):446-451. doi: 10.14202/vetworld.2020.446-451. Epub 2020 Mar 11.
3
Antibacterial-Agent-Immobilized Gelatin Hydrogel as a 3D Scaffold for Natural and Bioengineered Tissues.抗菌剂固定化明胶水凝胶作为天然组织和生物工程组织的3D支架
Gels. 2019 Jun 11;5(2):32. doi: 10.3390/gels5020032.
4
Structural and Kinetic Studies of the Potent Inhibition of Metallo-β-lactamases by 6-Phosphonomethylpyridine-2-carboxylates.6-膦酰甲基吡啶-2-羧酸盐对金属β-内酰胺酶的强效抑制作用的结构与动力学研究
Biochemistry. 2018 Mar 27;57(12):1880-1892. doi: 10.1021/acs.biochem.7b01299. Epub 2018 Mar 9.
5
Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of in a Tertiary Care Hospital of North India.在印度北部一家三级护理医院中，多立培南、美罗培南和亚胺培南对呼吸道分离菌的评估。
Indian J Crit Care Med. 2017 Oct;21(10):703-706. doi: 10.4103/ijccm.IJCCM_341_17.
6
Assessment of antibiotic resistance in Klebsiella pneumoniae exposed to sequential in vitro antibiotic treatments.对经序贯体外抗生素治疗的肺炎克雷伯菌的抗生素耐药性评估。
Ann Clin Microbiol Antimicrob. 2016 Dec 9;15(1):60. doi: 10.1186/s12941-016-0173-x.
7
A meta-analysis of efficacy and safety of doripenem for treating bacterial infections.多立培南治疗细菌感染的疗效和安全性的荟萃分析。
Braz J Infect Dis. 2015 Mar-Apr;19(2):156-62. doi: 10.1016/j.bjid.2014.10.010. Epub 2015 Jan 27.
8
Evaluation of doripenem utilization and susceptibilities at a large urban hospital.评价一家大型城市医院的多利培南利用情况和药敏结果。
Int J Clin Pharm. 2011 Dec;33(6):958-63. doi: 10.1007/s11096-011-9567-1. Epub 2011 Oct 8.
9
Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.连续静脉-静脉血液滤过和连续静脉-静脉血液透析滤过对多利培南处置的影响。
Antimicrob Agents Chemother. 2011 Mar;55(3):1187-93. doi: 10.1128/AAC.01063-10. Epub 2011 Jan 3.
本文引用的文献
1
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.多利培南对来自囊性纤维化和非囊性纤维化患者的铜绿假单胞菌和洋葱伯克霍尔德菌分离株的体外活性。
Antimicrob Agents Chemother. 2006 Feb;50(2):819-21. doi: 10.1128/AAC.50.2.819-821.2006.
2
Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).多利培南（S-4661）的抗菌活性：一项全球监测报告（2003年）
Clin Microbiol Infect. 2005 Dec;11(12):974-84. doi: 10.1111/j.1469-0691.2005.01271.x.
3
The antimicrobial armamentarium: evaluating current and future treatment options.抗菌药物库：评估当前及未来的治疗选择
Pharmacotherapy. 2005 Oct;25(10 Pt 2):55S-62S. doi: 10.1592/phco.2005.25.10part2.55S.
4
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.运用药代动力学-药效学目标达成分析来支持多利培南2期和3期给药策略。
Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7. doi: 10.1128/AAC.49.9.3944-3947.2005.
5
Activities of doripenem (S-4661) against drug-resistant clinical pathogens.多利培南（S-4661）对耐药临床病原体的活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3136-40. doi: 10.1128/AAC.48.8.3136-3140.2004.
6
Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.多黏菌素E与铜绿假单胞菌的体外研究：对特征明确的分离株、突变体和接合子的活性及耐药性选择潜力
Antimicrob Agents Chemother. 2004 Aug;48(8):3086-92. doi: 10.1128/AAC.48.8.3086-3092.2004.
7
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.多利培南（S-4661），一种新型碳青霉烯类抗生素：对当代病原体的比较活性，包括杀菌作用和初步体外方法评估。
J Antimicrob Chemother. 2004 Jul;54(1):144-54. doi: 10.1093/jac/dkh298. Epub 2004 Jun 9.
8
In vitro antimicrobial activity of doripenem, a new carbapenem.新型碳青霉烯类药物多利培南的体外抗菌活性
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96. doi: 10.1128/AAC.48.4.1384-1396.2004.
9
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.多利培南对具有特征性β-内酰胺酶的肠杆菌科细菌和不动杆菌属细菌的分离株、突变株及接合子的比较活性
Antimicrob Agents Chemother. 2004 Apr;48(4):1313-9. doi: 10.1128/AAC.48.4.1313-1319.2004.
10
In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.新型注射用碳青霉烯类药物S-4661对妇科病原体的体内外抗菌活性
J Antimicrob Chemother. 2000 Sep;46(3):471-4. doi: 10.1093/jac/46.3.471.
Zotero 插件